Xeris Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline Progress
06 mars 2019 16h10 HE
|
Xeris Pharmaceuticals, Inc.
Continuing to execute commercial build and launch readiness for Gvoke HypoPen™ Advancing pipeline of preclinical and clinical development-stage products Cash position of $112.6 million at year-end...
Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
01 mars 2019 16h15 HE
|
Xeris Pharmaceuticals, Inc.
CHICAGO, March 01, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals to Participate at SVB Leerink Global Healthcare Conference
20 févr. 2019 07h30 HE
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Feb. 20, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock
13 févr. 2019 19h26 HE
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Feb. 13, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces Proposed Public Offering of Shares of Common Stock
11 févr. 2019 16h05 HE
|
Xeris Pharmaceuticals, Inc.
CHICAGO, Feb. 11, 2019 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces Third Quarter 2018 Financial Results and Highlights Pipeline Progress
07 nov. 2018 08h00 HE
|
Xeris Pharmaceuticals, Inc.
Glucagon pen NDA accepted for review by FDA Continuing to execute commercial build and launch readiness for glucagon pen Advancing pipeline of preclinical and clinical development-stage products...
Xeris Pharmaceuticals Announces Second Quarter 2018 Financial Results and Business Highlights
13 août 2018 08h00 HE
|
Xeris Pharmaceuticals, Inc.
Successfully Completed Initial Public Offering (IPO) Submitted New Drug Application (NDA) for Glucagon Rescue Pen CHICAGO, Aug. 13, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (Nasdaq:...
Xeris Pharmaceuticals to Present at Two Upcoming Investor Conferences
31 juil. 2018 07h00 HE
|
Xeris Pharmaceuticals, Inc.
CHICAGO, July 31, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces New Board Members and New Executive to Management Team
30 juil. 2018 07h00 HE
|
Xeris Pharmaceuticals, Inc.
CHICAGO, July 30, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...
Xeris Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
26 juin 2018 16h15 HE
|
Xeris Pharmaceuticals, Inc.
CHICAGO, June 26, 2018 (GLOBE NEWSWIRE) -- Xeris Pharmaceuticals, Inc. (NASDAQ:XERS), a specialty pharmaceutical company leveraging its novel technology platforms to develop and commercialize...